American Journal of Clinical Dermatology

STRATA Skin Sciences to Host Virtual KOL Event on XTRAC® and TheraClear®X

Retrieved on: 
Thursday, August 24, 2023
KOL, Senior, Marketing, American Journal of Clinical Dermatology, Cosmetic, FAAD, Associate, Feinberg School of Medicine, SSKN, MD, Northwestern University, Hospital, Risk management, Dermatology

HORSHAM, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it will host a virtual key opinion leader (KOL) event on XTRAC® and TheraClear®X on Wednesday, September 20, 2023, at 10:00 AM – 12:00 PM ET.

Key Points: 
  • HORSHAM, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it will host a virtual key opinion leader (KOL) event on XTRAC® and TheraClear®X on Wednesday, September 20, 2023, at 10:00 AM – 12:00 PM ET.
  • To register for the event, click here .
  • STRATA’s CEO, Bob Moccia, will also provide a business update addressing the company’s current and future growth plans.
  • A replay will be available after the call on the company’s investor relations webpage.

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

Retrieved on: 
Wednesday, August 2, 2023
American Journal of Clinical Dermatology, Rosacea, Journey, FDA, MD, New Çeltek events, News, Marketing, Pharmaceutical industry

SCOTTSDALE, Ariz., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2023 financial results after the U.S. financial markets close on Tuesday, August 8, 2023. Journey Medical management and Neal Bhatia, MD, Director of Clinical Dermatology, Therapeutics Clinical Research, San Diego, CA and an investigator in over 75 clinical trials including the DFD-29 Phase 3 clinical program, will conduct a conference call and audio webcast on Tuesday, August 8, 2023 at 4:30 p.m. ET.

Key Points: 
  • Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m.
  • To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international).
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call.
  • Please note that registered participants will receive their dial-in number upon registration.

La Roche-Posay Supports University of Southern California's Skin of Color and Pigmentary Disorders Research Fellowship to Advance Skin of Color Dermatology

Retrieved on: 
Friday, February 10, 2023
Master of Science, USC, FAAD, Pigment, Medicine, X-linked reticulate pigmentary disorder, La Roche-Posay, American Journal of Clinical Dermatology, Patient, Keck School of Medicine of USC, Skin, Disease, University, Research, Mortality, Dermatology, Health equity, Associate, Student, Good, Education, Quality of life, Veterinary medicine, Nursing

The fellowship allows students, between their third and fourth year of medical school, the opportunity to conduct research related to ethnic skin conditions and pigmentary disorders that will advance skin of color dermatology.

Key Points: 
  • The fellowship allows students, between their third and fourth year of medical school, the opportunity to conduct research related to ethnic skin conditions and pigmentary disorders that will advance skin of color dermatology.
  • To create a comprehensive center of excellence, the program aims to increase education and research through the Skin of Color and Pigmentary Disorders Research Fellowship.
  • This year's Skin of Color and Pigmentary Disorders Research fellow is Sarah Gonzalez, a medical student from Wayne State in Detroit Michigan.
  • "The USC Skin of Color and Pigmentary Disorders Research Fellowship will help us move towards health equity for all," says Dr. Elbuluk.

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology

Retrieved on: 
Monday, November 28, 2022
Linda, Cream, Henry Ford Health System, PSD, Doctor of Philosophy, Henry Ford, DLQI, FAAD, PDE4, Safety, Week, Patient, Itch, Sleep, Paper, Dermatology Life Quality Index, American Journal of Clinical Dermatology, Disease, MD, Dermatitis, Psoriasis, American Journal, Atopic dermatitis, FDA, NRS, Silviculture, Pharmaceutical industry, Cosmetics, Hospital, Dermatology

In the parallel-group, double-blind, vehicle-controlled phase 2b clinical trial, 331 subjects ranging from ages 18 to 89 years were randomized to roflumilast 0.3% cream, roflumilast 0.15% cream or vehicle in a 1:1:1 ratio.

Key Points: 
  • In the parallel-group, double-blind, vehicle-controlled phase 2b clinical trial, 331 subjects ranging from ages 18 to 89 years were randomized to roflumilast 0.3% cream, roflumilast 0.15% cream or vehicle in a 1:1:1 ratio.
  • Roflumilast cream or vehicle was applied once daily to all psoriasis lesions for 12 weeks.
  • In July 2022, ZORYVE (roflumilast) cream 0.3% was approved for the topical use in adults and adolescents with mild to severe plaque psoriasis, including intertriginous psoriasis.
  • ZORYVE (roflumilast) cream 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.

LEO Pharma Announces Publication of Adbry™ (tralokinumab-ldrm) Efficacy Data in Moderate-to-Severe Atopic Dermatitis in American Journal of Clinical Dermatology

Retrieved on: 
Wednesday, July 20, 2022
FDA, Health, Clinical Trials, Research, Pharmaceutical, Science, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Atopic dermatitis, Itch, Eczema Area and Severity Index, Respiratory tract, Food, Anaphylaxis, TCS, Research, Incidence, Dermatitis, Adult, Safety, Allergy, NRS, Psoriasis Area and Severity Index, Quality of life, Clinical trial, Â, Tralokinumab, FDA, American Journal of Clinical Dermatology, Patient, Week, Vitamin, Hypersensitivity, Conjunctivitis, Syringe, Breast milk, Tell, LEO, Dermatology Life Quality Index, Pharmaceutical industry, Vaccine, Dietary supplement, Health insurance, Birth control, EASI, DLQI

LEO Pharma A/S, a global leader in medical dermatology, today announced that American Journal of Clinical Dermatology published 32-week results from a post-hoc analysis of the Phase 3 ECZTRA 3 clinical trial (NCT03363854) in atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced that American Journal of Clinical Dermatology published 32-week results from a post-hoc analysis of the Phase 3 ECZTRA 3 clinical trial (NCT03363854) in atopic dermatitis (AD).
  • The results provide additional context around the benefits of Adbry, including impact on measures that are important to clinicians and patients and, ultimately, may help inform clinical decisions.
  • ADBRY can cause serious side effects including:
    Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis.
  • Stop using ADBRY and tell your healthcare provider or get emergency help right away if you get any of the following symptoms: